Business
Expedition Raises $115M for a China-Licensed COPD Pill Targeting Inflammation
The Series B, led by General Atlantic, backs EXPD-101, a once-daily DPP1 inhibitor licensed from Fosun Pharma and now entering a global Phase 2 trial in COPD.